Tags

Type your tag names separated by a space and hit enter

Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development.

Abstract

OBJECTIVE

Human chorionic gonadotropin (hCG) has proliferative effects on uterine smooth muscle and leiomyoma tissue in vitro. We hypothesized that luteinizing hormone (LH) would have the same effect by activating the LH/hCG receptor, and it would follow that premenopausal women with higher basal LH levels would be more likely to have leiomyomata.

METHODS

Randomly selected women, aged 35 to 49 years, from a prepaid health plan were screened for leiomyomata with pelvic ultrasound. Urine samples collected during the first or last 5 days of the menstrual cycle were analyzed for LH by immunofluorometric assay, and concentrations were corrected for creatinine (n = 523). Logistic regression and Bayes analyses were used to evaluate the association of LH with presence and size of leiomyomata, adjusting for age, and other risk factors.

RESULTS

Women with higher LH were more likely to have leiomyomata (adjusted odds ratios for second and third tertiles were 1.7 and 2.0 compared with lower tertile; 95% confidence intervals, 1.0 to 2.7 and 1.2 to 3.4, respectively). The association was stronger for large leiomyomata. Bayes analyses designed to estimate LH effects on tumor onset separately from tumor growth showed significantly accelerated tumor onset but little evidence of effects on tumor growth. Age, an independent risk factor for leiomyomata, was not affected by inclusion of LH in the logistic models.

CONCLUSIONS

As hypothesized, women with higher LH were more likely to have leiomyomata, but this did not explain the age-related increase in leiomyomata during perimenopausal ages. Determining whether LH is causal or a marker for susceptibility will require further research.

Links

Authors+Show Affiliations

,

Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA. baird@niehs.nih.gov

,

Source

MeSH

Adult
African Americans
Bayes Theorem
Creatinine
European Continental Ancestry Group
Female
Humans
Leiomyoma
Logistic Models
Luteinizing Hormone
Menstrual Cycle
Middle Aged
Odds Ratio
Perimenopause
Premenopause
Ultrasonography
Uterine Neoplasms

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

16443507

Citation

Baird, Donna D., et al. "Luteinizing Hormone in Premenopausal Women May Stimulate Uterine Leiomyomata Development." Journal of the Society for Gynecologic Investigation, vol. 13, no. 2, 2006, pp. 130-5.
Baird DD, Kesner JS, Dunson DB. Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. J Soc Gynecol Investig. 2006;13(2):130-5.
Baird, D. D., Kesner, J. S., & Dunson, D. B. (2006). Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. Journal of the Society for Gynecologic Investigation, 13(2), pp. 130-5.
Baird DD, Kesner JS, Dunson DB. Luteinizing Hormone in Premenopausal Women May Stimulate Uterine Leiomyomata Development. J Soc Gynecol Investig. 2006;13(2):130-5. PubMed PMID: 16443507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. AU - Baird,Donna D, AU - Kesner,James S, AU - Dunson,David B, PY - 2005/06/26/received PY - 2006/1/31/pubmed PY - 2006/6/10/medline PY - 2006/1/31/entrez SP - 130 EP - 5 JF - Journal of the Society for Gynecologic Investigation JO - J. Soc. Gynecol. Investig. VL - 13 IS - 2 N2 - OBJECTIVE: Human chorionic gonadotropin (hCG) has proliferative effects on uterine smooth muscle and leiomyoma tissue in vitro. We hypothesized that luteinizing hormone (LH) would have the same effect by activating the LH/hCG receptor, and it would follow that premenopausal women with higher basal LH levels would be more likely to have leiomyomata. METHODS: Randomly selected women, aged 35 to 49 years, from a prepaid health plan were screened for leiomyomata with pelvic ultrasound. Urine samples collected during the first or last 5 days of the menstrual cycle were analyzed for LH by immunofluorometric assay, and concentrations were corrected for creatinine (n = 523). Logistic regression and Bayes analyses were used to evaluate the association of LH with presence and size of leiomyomata, adjusting for age, and other risk factors. RESULTS: Women with higher LH were more likely to have leiomyomata (adjusted odds ratios for second and third tertiles were 1.7 and 2.0 compared with lower tertile; 95% confidence intervals, 1.0 to 2.7 and 1.2 to 3.4, respectively). The association was stronger for large leiomyomata. Bayes analyses designed to estimate LH effects on tumor onset separately from tumor growth showed significantly accelerated tumor onset but little evidence of effects on tumor growth. Age, an independent risk factor for leiomyomata, was not affected by inclusion of LH in the logistic models. CONCLUSIONS: As hypothesized, women with higher LH were more likely to have leiomyomata, but this did not explain the age-related increase in leiomyomata during perimenopausal ages. Determining whether LH is causal or a marker for susceptibility will require further research. SN - 1556-7117 UR - https://www.unboundmedicine.com/medline/citation/16443507/Luteinizing_hormone_in_premenopausal_women_may_stimulate_uterine_leiomyomata_development_ L2 - https://medlineplus.gov/uterinefibroids.html DB - PRIME DP - Unbound Medicine ER -